Tyra Biosciences (TYRA) Other Non-Current Liabilities (2020 - 2024)
Tyra Biosciences (TYRA) reported Other Non-Current Liabilities of $3000.0 for Q4 2024, down 93.48% on a YoY basis from $46000.0 in Q1 2024, and down 72.73% quarter-over-quarter from $11000.0 in Q3 2024.
Tyra Biosciences (TYRA) Other Non-Current Liabilities (2020 - 2024) Analysis & Trends
Tyra Biosciences has reported Other Non-Current Liabilities for 5 years, with the latest figure at $3000.0 in Q4 2024.
- For the quarter ending Q4 2024, Other Non-Current Liabilities fell 93.48% year-over-year to $3000.0; the trailing twelve-month figure through Dec 2024 stood at $3000.0 (down 93.48% YoY), and the FY2024 full-year result was $3000.0, down 93.48% from the prior year.
- Other Non-Current Liabilities for Q4 2024 stood at $3000.0, down from $11000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $434000.0 in Q3 2021, with the low at $3000.0 in Q4 2024.
- Historically, Other Non-Current Liabilities has averaged $155533.3 across 5 years, with a median of $139000.0 in 2023.
- Annual changes were most pronounced in 2021 — Other Non-Current Liabilities jumped 162.14% — and 2024, when it tumbled 93.48%.
- Tyra Biosciences' Other Non-Current Liabilities stood at $140000.0 in 2020, then jumped by 162.14% to $367000.0 in 2021, then slumped by 53.95% to $169000.0 in 2022, then plunged by 72.78% to $46000.0 in 2023, then plunged by 93.48% to $3000.0 in 2024.
- The last three Other Non-Current Liabilities figures came in at $3000.0 (Q4 2024), $11000.0 (Q3 2024), and $20000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Tyra Biosciences | 1.67 Bn | 1.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 11,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 29,000.00 |
| Dec 31, 2023 | 46,000.00 |
| Sep 30, 2023 | 77,000.00 |
| Jun 30, 2023 | 108,000.00 |
| Mar 31, 2023 | 139,000.00 |
| Dec 31, 2022 | 169,000.00 |
| Sep 30, 2022 | 226,000.00 |
| Jun 30, 2022 | 261,000.00 |
| Mar 31, 2022 | 303,000.00 |
| Dec 31, 2021 | 367,000.00 |
| Sep 30, 2021 | 434,000.00 |
| Dec 31, 2020 | 140,000.00 |